Detalhe da pesquisa
1.
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Eur J Clin Pharmacol
; 75(1): 41-49, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30191262
2.
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
J Neuroinflammation
; 14(1): 172, 2017 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859672
3.
Dysphagia for medication in Parkinson's disease.
NPJ Parkinsons Dis
; 8(1): 156, 2022 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36371409
4.
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Clin Pharmacol Drug Dev
; 9(8): 1015-1024, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32237115
5.
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.
Clin Pharmacol Drug Dev
; 8(1): 49-59, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29786964
6.
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.
Epilepsia
; 46(7): 1046-54, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16026556